These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28333573)

  • 21. Lactococcus lactis-based vaccines from laboratory bench to human use: an overview.
    Bahey-El-Din M
    Vaccine; 2012 Jan; 30(4):685-90. PubMed ID: 22154771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Stability of Parainfluenza Virus 5-Vectored Human Respiratory Syncytial Virus Vaccine Candidates after
    Phan SI; Adam CM; Chen Z; Citron M; Liang X; Espeseth AS; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses.
    Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L
    Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a real-time RT-PCR assay for the quantification of rabies virus as quality control of inactivated rabies vaccines.
    Lourenç Correia Moreira B; Aparecida Pereira L; Lappas Gimenez AP; Minor Fernandes Inagaki J; Raboni SM
    J Virol Methods; 2019 Aug; 270():46-51. PubMed ID: 31047970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly sensitive detection of mutations in CHO cell recombinant DNA using multi-parallel single molecule real-time DNA sequencing.
    Cartwright JF; Anderson K; Longworth J; Lobb P; James DC
    Biotechnol Bioeng; 2018 Jun; 115(6):1485-1498. PubMed ID: 29427433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.
    Chang JY; Chang CP; Tsai HH; Lee CD; Lian WC; Ih-Jen-Su ; Sai IH; Liu CC; Chou AH; Lu YJ; Chen CY; Lee PH; Chiang JR; Chong PC
    Vaccine; 2012 Jan; 30(4):703-11. PubMed ID: 22142585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.
    Ampofo WK; Azziz-Baumgartner E; Bashir U; Cox NJ; Fasce R; Giovanni M; Grohmann G; Huang S; Katz J; Mironenko A; Mokhtari-Azad T; Sasono PM; Rahman M; Sawanpanyalert P; Siqueira M; Waddell AL; Waiboci L; Wood J; Zhang W; Ziegler T;
    Vaccine; 2015 Aug; 33(36):4368-82. PubMed ID: 26148877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
    Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine provision: Delivering sustained & widespread use.
    Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
    Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tracing and control of raw materials sourcing for vaccine manufacturers.
    Faretra Peysson L
    Biologicals; 2010 May; 38(3):352-3. PubMed ID: 20335052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease.
    Stewart HJ; Fong-Wong L; Strickland I; Chipchase D; Kelleher M; Stevenson L; Thoree V; McCarthy J; Ralph GS; Mitrophanous KA; Radcliffe PA
    Hum Gene Ther; 2011 Mar; 22(3):357-69. PubMed ID: 21070114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA).
    Jordan I; Horn D; Thiele K; Haag L; Fiddeke K; Sandig V
    Virol Sin; 2020 Apr; 35(2):212-226. PubMed ID: 31833037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microarray-based gene expression analysis as a process characterization tool to establish comparability of complex biological products: scale-up of a whole-cell immunotherapy product.
    Wang M; Senger RS; Paredes C; Banik GG; Lin A; Papoutsakis ET
    Biotechnol Bioeng; 2009 Nov; 104(4):796-808. PubMed ID: 19591186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Principles of optimization and scaling of certain processes in the vaccine production technology. 3. Method of determination of the optimal method of thermal sterilization of sugar solutions].
    Matveev VE; Tarasenko VM; Vorob'ev AA; Smirnov EV
    Zh Mikrobiol Epidemiol Immunobiol; 1978 Jan; (1):118-23. PubMed ID: 629124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A practical approach for exploration and modeling of the design space of a bacterial vaccine cultivation process.
    Streefland M; Van Herpen PF; Van de Waterbeemd B; Van der Pol LA; Beuvery EC; Tramper J; Martens DE; Toft M
    Biotechnol Bioeng; 2009 Oct; 104(3):492-504. PubMed ID: 19598176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell substrates for the production of viral vaccines.
    Aubrit F; Perugi F; Léon A; Guéhenneux F; Champion-Arnaud P; Lahmar M; Schwamborn K
    Vaccine; 2015 Nov; 33(44):5905-12. PubMed ID: 26187258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vector-based genetically modified vaccines: Exploiting Jenner's legacy.
    Ramezanpour B; Haan I; Osterhaus A; Claassen E
    Vaccine; 2016 Dec; 34(50):6436-6448. PubMed ID: 28029542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Laboratories which produce veterinary vaccines.
    Randall DC
    Rev Sci Tech; 1998 Aug; 17(2):568-77. PubMed ID: 9713896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agility in adversity: Vaccines on Demand.
    De Groot AS; Moise L; Olive D; Einck L; Martin W
    Expert Rev Vaccines; 2016 Sep; 15(9):1087-91. PubMed ID: 27389971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.